

Clinical trials of diuretics for heart failure in all type of patients

TrialResults-center www.trialresultscenter.org

1 adenosine A1 receptor antagonist

Trial	Treatments	Patients	Trials design and methods
rolofylline vs placebo			
PROTECT-1 [NCT00328692] n=NA	-	-	

References

PROTECT-1, :

2 aldosterone-receptor blockers

Trial	Treatments	Patients	Trials design and methods
spironolactone vs control			
Cicoira , 2002 n=54/52 follow-up: 12 months	spironolactone 12.5 to 50 mg/day versus control	patients with chronic heart failure	Parallel groups open
Cicoira , 2004 n=47/46 follow-up: 12 months	spironolactone versus control	chronic heart failure patients	open
Ramires , 2000 n=19/16 follow-up: 20 weeks	spironolactone versus standard medical treatment	patients with systolic dysfunction and NYHA class III CHF secondary to dilated or ischemic cardiomyopathy	Parallel groups open
eplerenone vs placebo			
EMPHASIS-HF , 2010 [NCT00232180] n=1364/1373 follow-up: 21 months	eplerenone versus placebo	patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35%	Parallel groups double blind 29 countries
REMODEL ongoing [NCT00082589] n=NA follow-up:	Eplerenone versus placebo	Patients with left ventricular systolic dysfunction (EF Less Than or Equal to 35%) and mild to moderate heart failure	Parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
<i>Weir ongoing</i> [NCT00132093] n=NA follow-up: 6 montsh	eplerenone versus placebo	patients with acute myocardial infarction	Parallel groups double blind
spironolactone vs placebo			
<i>Agostoni , 2005</i> n=14/15 follow-up: 6 months	spironolactone 25mg/d versus placebo	stable chronic heart failure patients with reduced influences lung diffusion (DLCO)	Parallel groups open Italy
<i>Barr , 1995</i> n=28/14 follow-up: 8 weeks	spironolactone 50 to 100 mg/day, titrated to blood pressure and plasma potassium (added to an angiotensin-converting enzyme inhibitor) versus placebo	patients with New York Heart Association II to III congestive heart failure	Parallel groups double blind
<i>Farquharson , 2000</i> n=10/10 follow-up: 4 weeks	spironolactone 50 mg/d versus placebo	patients with NYHA class II to III chronic heart failure on standard diuretic/ACE inhibitor therapy	double blind
<i>Macdonald , 2004</i> n=43/43 follow-up: 3 months	spironolactone 12.5-50 mg/d versus placebo	patients with New York Heart Association class I-II congestive heart failure taking optimal treatment (including beta blockers)	Cross over double blind
<i>MacFadyen , 1997</i> n=21/16 follow-up: 8 weeks	spironolactone (50-100 mg/day) versus placebo	patients with stable chronic heart failure	Parallel groups double blind
<i>Mottram , 2004</i> n=30 follow-up: 6 months	spironolactone 25 mg/d versus placebo	hypertensive patients with diastolic heart failure	double blind
<i>RALES , 1998</i> n=822/841 follow-up: 24 mo	spironolactone (25 to 50 mg daily) versus placebo	patients with severeheart failure	Parallel groups Open World
<i>Tsutamoto , 2001</i> n=20/17 follow-up: 12 weeks	spironolactone 25 mg daily versus placebo	patients with mild-to-moderate nonischemic congestive heart failure	Parallel groups double blind Japan
<i>Yee , 2001</i> n=28/28 follow-up: 4 weeks	spironolactone 50mg/d versus placebo	patients with New York Heart Association class II to IV congestive heart failure	double blind
<i>PIE II ongoing</i> [NCT00123955] n=NA follow-up: 9 months	Spironolactone 25mg tablet daily for 9 months versus placebo	elderly patients with isolated diastolic heart failure	Parallel groups double blind
spironolactone+captopril vs captopril			

continued...

Trial	Treatments	Patients	Trials design and methods
Han , 1994 n=19/16 follow-up: 4 weeks	captopril plus spironolactone versus captopril alone	patients with refractory CHF and New York Heart Association functional class IV without renal dysfunction, hypotension and hyperkalemia	open China
aldactone vs furosemide			
Bednarz , 2000 n=11/10 follow-up:	Aldactone 200 mg i.v versus furosemide 20 mg i.v	patients with NYHA class III to IV congestive heart failure	open
spironolactone+furosemide vs spironolactone+butizide			
Mauersberger , 1985 n=22 follow-up:	spironolactone 50mg + furosemide 20 mg versus spironolactone 50mg + butizide 5mg	patients with congestive heart failure	open

References

Cicoira, 2002:

Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P, Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. *J Am Coll Cardiol* 2002;40:304-10. [[12106936](#)]

Cicoira, 2004:

Cicoira M, Rossi A, Bonapace S, Zanolla L, Perrot A, Francis DP, Golia G, Franceschini L, Osterziel KJ, Zardini P, Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. *Am J Med* 2004;116:657-61. [[15121491](#)] [10.1016/j.amjmed.2003.12.033](#)

Ramires, 2000:

Ramires FJ, Mansur A, Coelho O, Maranhão M, Gruppi CJ, Mady C, Ramires JA, Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. *Am J Cardiol* 2000;85:1207-11. [[10802002](#)]

EMPHASIS-HF, 2010:

Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). *Eur J Heart Fail* 2010;12:617-22 [[20388647](#)] [10.1093/eurjhf/hfq049](#)

Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). *Eur J Heart Fail* 2010;12:617-22 [[20388647](#)] [10.1093/eurjhf/hfq049](#)

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. *N Engl J Med* 2010 Nov 14; [[21073363](#)] [10.1056/NEJMoa1009492](#)

REMODEL, :

Weir, :

Agostoni, 2005:

Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P, Spironolactone improves lung diffusion in chronic heart failure. *Eur Heart J* 2005;26:159-64. [[15618072](#)] [10.1093/eurheartj/ehi023](#)

Barr, 1995:

Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD, Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. *Am J Cardiol* 1995;76:1259-65. [[7503007](#)]

Farquharson, 2000:

Farquharson CA, Struthers AD, Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. *Circulation* 2000;101:594-7. [[10673249](#)]

Macdonald, 2004:

Macdonald JE, Kennedy N, Struthers AD, Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. *Heart* 2004;90:765-70. [[15201246](#)] [10.1136/hrt.2003.017368](#)

MacFadyen, 1997:

MacFadyen RJ, Barr CS, Struthers AD, Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. *Cardiovasc Res* 1997;35:30-4. [[9302344](#)]

Mottram, 2004:

Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH, Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. *Circulation* 2004;110:558-65. [[15277317](#)] [10.1161/01.CIR.0000138680.89536.A9](#)

RALES, 1998:

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). *Am J Cardiol* 1996;78:902-7 [[8888663](#)]

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;341:709-17 [[10471456](#)]

Pitt D, ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). *Eur Heart J* 1995;16 Suppl N:107-10. [[8682055](#)]

Tsutamoto, 2001:

Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M, Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. *J Am Coll Cardiol* 2001;37:1228-33. [[11300427](#)]

Yee, 2001:

Yee KM, Pringle SD, Struthers AD, Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. *J Am Coll Cardiol* 2001;37:1800-7. [[11401114](#)]

PIE II, :**Han, 1994:**

Han YL, Tong M, Jing QM, Hu XL, Liu JQ, Combined therapy of captopril and spironolactone for refractory congestive heart failure. *Chin Med J (Engl)* 1994;107:688-92. [[7805462](#)]

Bednarz, 2000:

Bednarz B, Cybulski J, Chamiec T, [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure] *Pol Merkuriusz Lek* 2000;9:519-21. [[11081314](#)]

Bednarz B, Cybulski J, Chamiec T [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure] *Pol Merkuriusz Lek* 2000 Aug;9:519-21 [[11081314](#)]

Mauersberger, 1985:

Mauersberger H, Rangoonwala B, Ehrlich E, [Comparative study of 2 diuretic-containing combination preparations in patients with edematous heart failure] *Wien Med Wochenschr* 1985;135:205-13. [[4013351](#)]

3 device

Trial	Treatments	Patients	Trials design and methods
Ultrafiltration vs Diuretics			

continued...

Trial	Treatments	Patients	Trials design and methods
UNLOAD [NCT00124137] n=NA follow-up:	Ultrafiltration (Aquadex system) versus IV Diuretics	Patients Hospitalized for Acute Decompensated Heart Failure	Parallel groups open

References

UNLOAD, :

Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83 [17291932]

4 Diuretics

Trial	Treatments	Patients	Trials design and methods
amiloride vs placebo			
Cheitlin , 1991 n=12/12 follow-up: 12 weeks	amiloride versus placebo	men with a history of congestive heart failure	Cross over double blind
diuretic agents vs placebo			
Burr , 1977 n=52/54 follow-up: 12 weeks	diuretic agents versus placebo (withdrawals)	elderly patients taking long-term diuretics	Parallel groups double blind
furosemide vs placebo			
Mathur , 1984 n=5/5 follow-up:	furosemide hydrochlorotiazide versus placebo	patient with pulmonary heart disease due to severe chronic airflow obstruction and clinical features of congestive heart failure during respiratory failure	Cross over double blind
piretanide vs placebo			
Sherman , 1986 n=20/18 follow-up: 4 weeks	piretanide versus placebo	patients with mild to moderately severe congestive heart failure	Parallel groups double blind
spironolactone vs placebo			
Agostoni , 2005 n=14/15 follow-up: 6 months	spironolactone 25mg/d versus placebo	stable chronic heart failure patients with reduced influences lung diffusion (DLCO)	Parallel groups open Italy
Barr , 1995 n=28/14 follow-up: 8 weeks	spironolactone 50 to 100 mg/day, titrated to blood pressure and plasma potassium (added to an angiotensin-converting enzyme inhibitor) versus placebo	patients with New York Heart Association II to III congestive heart failure	Parallel groups double blind

continued...

Trial	Treatments	Patients	Trials design and methods
Farquharson , 2000 n=10/10 follow-up: 4 weeks	spironolactone 50 mg/d versus placebo	patients with NYHA class II to III chronic heart failure on standard diuretic/ACE inhibitor therapy	double blind
Macdonald , 2004 n=43/43 follow-up: 3 months	spironolactone 12.5-50 mg/d versus placebo	patients with New York Heart Association class I-II congestive heart failure taking optimal treatment (including beta blockers)	Cross over double blind
MacFadyen , 1997 n=21/16 follow-up: 8 weeks	spironolactone (50-100 mg/day) versus placebo	patients with stable chronic heart failure	Parallel groups double blind
Mottram , 2004 n=30 follow-up: 6 months	spironolactone 25 mg/d versus placebo	hypertensive patients with diastolic heart failure	double blind
RALES , 1998 n=822/841 follow-up: 24 mo	spironolactone (25 to 50 mg daily) versus placebo	patients with severe heart failure	Parallel groups Open World
Tsutamoto , 2001 n=20/17 follow-up: 12 weeks	spironolactone 25 mg daily versus placebo	patients with mild-to-moderate nonischemic congestive heart failure	Parallel groups double blind Japan
Yee , 2001 n=28/28 follow-up: 4 weeks	spironolactone 50mg/d versus placebo	patients with New York Heart Association class II to IV congestive heart failure	double blind
PIE II ongoing [NCT00123955] n=NA follow-up: 9 months	Spiro lactone 25mg tablet daily for 9 months versus placebo	elderly patients with isolated diastolic heart failure	Parallel groups double blind
various diuretics vs placebo			
De jong , 1994 n=29/34 follow-up: 8 weeks	diuretics versus placebo (diuretics withdrawal)	patients aged 65 years or older and taking diuretic drugs	Parallel groups double blind the Netherlands
Myers , 1982 n=77 follow-up: 52 weeks	various diuretics versus placebo (withdrawals)	elderly not receiving concurrent digoxin therapy	Parallel groups double blind
Walma , 1997 n=100/102 follow-up: 14 weeks	various diuretics versus placebo (withdrawals)	elderly patients taking long-term diuretics without manifest heart failure or hypertension	Parallel groups double blind
hydrochlorothiazide vs benazepril			
Nordrehaug , 1992 n=29/29 follow-up: 8 weeks	hydrochlorothiazide 50 mg daily versus benazepril 20 mg daily	patients with symptomatic (NYHA functional class 2) mild heart failure	Cross over double blind
frusemide plus amiloride vs captopril			

continued...

Trial	Treatments	Patients	Trials design and methods
Richardson , 1987 n=14/14 follow-up: 8 weeks	frusemide plus amiloride versus captopril	patients who had previously been treated with diuretics	Cross over double blind
furosemide vs captopril			
Boccanelli , 1986 n=8/7 follow-up: 13 weeks	furosemide 25 to 100 mg od versus captopril 12.5 to 50 mg bid +furosemide 25mg od	patients with moderate congestive heart failure not completely controlled on digoxin (0.25 mg o.d.) and frusemide (25 mg o.d.),	Parallel groups double blind
Cowley , 1986 n=10/10 follow-up:	furosemide (increased doses of frusemide) versus captopril (addition)	patients with moderate heart failure who still had symptoms despite 40 mg frusemide daily	Cross over double blind
hydrochlorothiazide+triamterene vs digoxin			
Sievert , 1989 n=16/16 follow-up: 5 weeks	hydrochlorothiazide+triamterene versus digoxin	patients in heart failure and sinus rhythm	Cross over double blind
piretanide vs digoxin			
Haerer , 1989 n=14/14 follow-up:	piretanide versus digoxin	-	Parallel groups double blind
furosemide + spironolactone vs prenalterol			
Dalhstrom , 1986 n=10/10 follow-up: 12 weeks	intensified treatment with diuretics (furosemide- spironolactone) versus prenalterol 100-200 mg daily in addition to their basal treatment	patients with severe chronic congestive heart failure (CHF) due to ischaemic heart disease treated with digitalis and diuretics	Cross over double blind

References

Cheitlin, 1991:

Cheitlin MD, Byrd R, Benowitz N, Liu E, Modin G Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics. *Cardiovasc Drugs Ther* 1991;5:719-25 [[1888694](#)]

Burr, 1977:

Burr ML, King S, Davies HE, Pathy MS., *imag* The effects of discontinuing long-term diuretic therapy in elderly *Age & Ageing* 1977;6:3845

Burr ML, King S, Davies HE, Pathy MS The effects of discontinuing long-term diuretic therapy in the elderly. *Age Ageing* 1977;6:38-45 [[402800](#)]

Mathur, 1984:

Mathur PN, Pugsley SO, Powles AC, McEwan MP, Campbell EJ Effect of diuretics on cardiopulmonary performance in severe chronic airflow obstruction. A controlled clinical trial. *Arch Intern Med* 1984;144:2154-7 [[6388521](#)]

Sherman, 1986:

Sherman LG, Liang CS, Baumgardner S, Charuzi Y, Chardo F, Kim CS Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. *Clin Pharmacol Ther* 1986;40:587-94 [[3533372](#)]

Agostoni, 2005:

Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P, Spironolactone improves lung diffusion in chronic heart failure. *Eur Heart J* 2005;26:159-64. [[15618072](#)] [10.1093/eurheartj/ehi023](#)

Barr, 1995:

Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD, Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. *Am J Cardiol* 1995;76:1259-65. [[7503007](#)]

Farquharson, 2000:

Farquharson CA, Struthers AD, Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. *Circulation* 2000;101:594-7. [[10673249](#)]

Macdonald, 2004:

Macdonald JE, Kennedy N, Struthers AD, Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. *Heart* 2004;90:765-70. [[15201246](#)] [10.1136/hrt.2003.017368](#)

MacFadyen, 1997:

MacFadyen RJ, Barr CS, Struthers AD, Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. *Cardiovasc Res* 1997;35:30-4. [[9302344](#)]

Mottram, 2004:

Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH, Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. *Circulation* 2004;110:558-65. [[15277317](#)] [10.1161/01.CIR.0000138680.89536.A9](#)

RALES, 1998:

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). *Am J Cardiol* 1996;78:902-7 [[8888663](#)]

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;341:709-17 [[10471456](#)]

Pitt D, ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). *Eur Heart J* 1995;16 Suppl N:107-10. [[8682055](#)]

Tsutamoto, 2001:

Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M, Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. *J Am Coll Cardiol* 2001;37:1228-33. [[11300427](#)]

Yee, 2001:

Yee KM, Pringle SD, Struthers AD, Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. *J Am Coll Cardiol* 2001;37:1800-7. [[11401114](#)]

PIE II, :**De jong, 1994:**

de Jonge JW, Knottnerus JA, van Zutphen WM, de Bruijne GA, Struijker Boudier HA Short term effect of withdrawal of diuretic drugs prescribed for ankle oedema. *BMJ* 1994;308:511-3 [[8136670](#)]

Myers, 1982:

Myers MG, Weingert ME, Fisher RH, Gryfe CI, Shulman HS Unnecessary diuretic therapy in the elderly. *Age Ageing* 1982;11:213-21 [[7180724](#)]

Walma, 1997:

Walma EP, Hoes AW, van Dooren C, Prins A, van der Does E Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial. *BMJ* 1997;315:464-8 [[9284668](#)]

Nordrehaug, 1992:

Nordrehaug JE, Omsj IH, Vollset SE A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure. *J Intern Med* 1992;231:589-94 [[1619382](#)]

Richardson, 1987:

Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. *Lancet* 1987;2:709-11 [2888942]

Boccanelli, 1986:

Boccanelli A, Zachara E, Liberatore SM, Carboni GP, Prati PL Addition of captopril versus increasing diuretics in moderate but deteriorating heart failure: a double-blind comparative trial. *Postgrad Med J* 1986;62 Suppl 1:184-7 [3534859]

Cowley, 1986:

Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. *Lancet* 1986;2:770-2 [2876233]

Sievert, 1989:

Sievert H, Offermann T, Hopf R, Kaltenbach M, Bussmann WD [Basic therapy of chronic heart failure with digitalis or diuretics?] *Dtsch Med Wochenschr* 1989;114:363-7 [2924690]

Haerer, 1989:

Haerer W, Hetzel M, Fehske KL, Fehske KL, Stauch M. [mage/pj](#) The impact of digoxin and diuretics on exercise tolerance in congestive heart failure: a placebo controlled randomised double-blind trial. *alio Circulation* 1989;80:1698A

Dahlstrom, 1986:

Jorde R, Pettersen JE, Burhol PG Lack of effect of exogenous or endogenous gastric inhibitory polypeptide on the elimination rate of Intralipid in man. *Acta Med Scand* 1984;216:19-23 [6485877]

Dahlstrm U, Areskog M, Wranne B, Karlsson E Prenalterol as long-term therapy for chronic congestive heart failure. A randomized cross-over trial. *Acta Med Scand* 1984;216:199-207 [6149671]

5 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.